https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2004-02-23 14:39:182016-11-28 14:39:41SuperGen Inc. Announces Intent to Withdraw the Registration Statement for Public Offering of Shares of Common Stock
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2004-02-13 14:39:502016-11-28 14:40:10SuperGen Announces Interim Data from Dacogen™ Phase III Clinical Study in Myelodysplastic Syndrome
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2004-02-04 14:40:192016-11-28 14:40:40SuperGen, Inc. Announces Filing of Registration Statement for Public Offering of Shares of Common Stock
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2004-01-30 14:40:492016-11-28 14:41:12SuperGen Announces Resignation of Dr. Craig Rosenfeld To Pursue Start-Up Opportunity
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2004-01-27 14:41:232016-11-28 14:41:43SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2004-01-23 14:41:542016-11-28 14:42:18Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome
